This week, Fluorobiotech’s COO, Ross Rayne Vermeulen, attended a landmark event in Johannesburg celebrating the launch of clinical trials for South Africa’s first domestically developed cholera vaccine, a major achievement led by Biovac. The ceremony marked the start of Phase I safety trials, representing a pivotal advancement not only for...
Fluorobiotech Engages Key Stakeholders at Africa Tech Festival to Advance Biotechnology Innovation Across the Continent
Last week, Fluorobiotech representatives Ross Rayne Vermeulen and Marthinus Janse van Vuuren attended the Africa Tech Festival, one of the continent’s leading gatherings for innovators, investors, policymakers, and technology developers. Their participation offered a timely opportunity to position biotechnology within the broader African innovation agenda and to highlight Fluorobiotech’s growing...
Fluorobiotech Hosts Medicines Patent Pool Representatives for Strategic Discussions on Advancing Africa’s mRNA and Enzyme Manufacturing Capabilities
Last week, Fluorobiotech had the pleasure of welcoming representatives from the Medicines Patent Pool (MPP), Dr. Monica Moschioni (PhD, MPH) and Umut Demirtas to our laboratory at Stellenbosch University’s LaunchLab. Their visit formed part of ongoing efforts to strengthen partnerships that support Africa’s growing biotechnology and mRNA manufacturing ecosystems. We...
mRNA Vaccination Shows Promise in Enhancing Cancer Immunotherapy: New Insights for the Future of Immune-Modulating Technologies
A landmark study presented at the 2025 European Society for Medical Oncology (ESMO) Congress by The University of Texas MD Anderson Cancer Center has provided compelling new evidence that mRNA technology may play a far greater therapeutic role than previously understood. While mRNA platforms gained global attention for their rapid...